MSDS Cryopreserved Cells
Instructions HCASMC Normal
Cell Apps Flyer Smooth Muscle Cells
Cell Apps Flyer Cardiovascular Cells
5 Important Cell Culture Rules
Cell Apps Poster Primary Cells
Cell Applications Inc Brochure
Human Coronary Artery Smooth Muscle Cells (HCASMC) provide an excellent model system to study all aspects of cardiovascular function and disease, especially those related to mechanisms of hyperplasia and hypertrophy of intimal smooth muscle cells leading to vascular occlusion in atherosclerosis and stent restenosis.
HCASMC from Cell Applications, Inc. have been utilized in a number of research studies, for example, to:
- Study signaling pathways regulating smooth muscle differentiation and chronic inflammation of arterial wall that leads to artherosclerosis
- Demonstrate that STAT-1 and STAT-3 regulate VEGF production in smooth muscle cells by having opposing effects on HIF-1α expression
- Examine the mechanisms of hypoxia and reoxigenation injuries in by demonstrating increased production of ROS and inflammatory cytokines, and further showing that DHA is not beneficial in this type of injuries
- Investigate (by also using human Internal Thoracic Artery Smooth Muscle Cells obtained from Cell Applications, Inc.), the gene expression differences between smooth muscle cells from different arteries, underlying their differential response to injuries and proliferation stimuli
- Suggest the hypermethylation of SOCS3 gene as the connection between TNF-α and IGF-1 released in response to mechanical injury during coronary intervention, and the induction of cytokines leading to intimal hyperplasia and restenosis
- Develop a novel VEGFR/MET-targeted inhibitor with improved antitumor efficacy and decreased toxicity
- Investigate novel therapies and drug combinations to achieve optimal target selectivity
- Generate elastic scaffolds for tissue engineering and novel treatment strategies to prevent stent restenosis by designing new materials, or drug therapies to preferentially inhibit smooth muscle cell growth
Characterization: positive for smooth muscle cell specific alpha-actin expression
Normal healthy human coronary artery
No bacteria, yeast, fungi, mycoplasma, virus
Smooth muscle specific α-actin positive
|Attach, spread, proliferate in Growth Med|
500,000 HCASMC (2nd passage) frozen in Basal Medium w/ 10% FBS, 10% DMSO
Cryovial frozen HCASMC (350-05a), Growth Medium (311-500), Subcltr Rgnt Kit (090K)
Shipped in Gr Med, 3rd psg (flasks or plates)
At least 16
Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use.
|Cryopreserved HCASMC, Adult: 5x10^5 Cells (Adult), Medium & Subculture Reagents (See Details tab for specifics)||Size: 1 Kit||CAT.#: 350K-05a||Price: $885.00|
|Cryopreserved HCASMC, Adult: Frozen HCASMC (5x10^5)||Size: 1 Cryovial||CAT.#: 350-05a||Price: $735.00|
|Proliferating HCASMC, Adult: Actively growing, dividing cells in medium||Size: T-25 Flask||CAT.#: 351-25a||Price: $748.00|
|Proliferating HCASMC, Adult: Actively growing, dividing cells in medium||Size: T-75 Flask||CAT.#: 351-75a||Price: $925.00|
|Proliferating HCASMC, Adult: Actively growing, dividing cells in medium||Size: 6 Well||CAT.#: 351-6Wa||Price: $925.00|
|Proliferating HCASMC, Adult: Actively growing, dividing cells in medium||Size: 96 Well||CAT.#: 351-96Wa||Price: $1,058.00|
|Cryopreserved HCASMC Pooled, Adult: Frozen HCASMC (5x10^5)||Size: 1 Cryovial||CAT.#: 350p-05a||Price: $735.00|
|Cryopreserved HCASMC Pooled, Adult: 5x10^5 Cells (Pooled, Adult), Medium & Subculture Reagents (See Details tab for specifics)||Size: 1 Kit||CAT.#: 350pK-05a||Price: $885.00|
|Cryopreserved HCASMC Plaque, Adult: 5x10^5 Cells (Plaque, Adult), Medium & Subculture Reagents (See Details tab for specifics)||Size: 1 Kit||CAT.#: 350qK-05a||Price: $944.00|
|Cryopreserved HCASMC Plaque, Adult: Frozen HCASMC (5x10^5)||Size: 1 Cryovial||CAT.#: 350q-05a||Price: $794.00|
|Cryopreserved HCASMC-AS, Adult: Frozen HCASMC-AS from donor with Asthma (5x10^5)||Size: 1 Cryovial||CAT.#: 350AS-05a||Price: $802.00|
|Cryopreserved HCASMC-AS, Adult: 5x10^5 Cells (from donor with Asthma, Adult), Medium & Subculture Reagents (See Details tab for specifics)||Size: 1 Kit||CAT.#: 350ASK-05a||Price: $952.00|
|HCASMC Conditioned Medium: HCASMC Conditioned Medium||Size: 5 ml||CAT.#: 350cm-005||Price: $48.00|
|Human SMC Basal Medium: Basal medium (contains no growth supplement). Add GS before use.||Size: 500 ml||CAT.#: 310-500||Price: $57.00|
|Human SMC Differentiation Medium: Promotes cells to change from one type to another, more specialized||Size: 250 ml||CAT.#: 311D-250||Price: $73.00|
|Human SMC Growth Medium: All-in-one ready-to-use||Size: 500 ml||CAT.#: 311-500||Price: $105.00|
|Human SMC Growth Medium Kit: Basal medium & growth supplement sold together packaged separately||Size: Yields 500ml||CAT.#: 311K-500||Price: $113.00|
|Human SMC Growth Supplement: Added to Basal Medium to create Growth Medium||Size: 30 ml||CAT.#: 311-GS||Price: $57.00|
Extended Family Products
|Mouse Interleukin-6 Antibody: Mouse Interleukin-6 Antibody||Size: 100 ul||CAT.#: CP10325||Price: $302.00|
|Cyto-X Cell Counting Reagent: 500 tests||Size: 1 Bottle||CAT.#: 028-01||Price: $139.00|
|Cyto-X Cell Counting Reagent Sample: 100 tests||Size: Sample||CAT.#: 028-S||Price: $36.00|
|Cytofect™ Smooth Muscle Cell Transfection Kit: 125 x 24-Well||Size: 1 Kit||CAT.#: TF350K||Price: $285.00|
|Cytofect™ Smooth Muscle Cell Transfection Kit: 25 x 24-Well Rxns||Size: 1 Sample Kit||CAT.#: TF350KS||Price: $54.00|
|HCASMC RNA, Adult: Total RNA prepared from Human Coronary Artery Smooth Muscle Cells, adult||Size: 10 ug||CAT.#: 350-R10a||Price: $350.00|
|HCASMC RNA, Adult: Total RNA prepared from Human Coronary Artery Smooth Muscle Cells, adult||Size: 25 ug||CAT.#: 350-R25a||Price: $700.00|
|Human Heart RNA: Total RNA prepared from human heart tissue||Size: 50 ug||CAT.#: 1H30-50||Price: $139.00|
|Human Heart RNA: Total RNA prepared from human heart tissue||Size: 250 ug||CAT.#: 1H30-250||Price: $522.00|
|Human Interleukin-6 (IL-6): Human Interleukin-6||Size: 20 ug||CAT.#: RP1010-20||Price: $194.00|
|Human Interleukin-6 (IL-6): Human Interleukin-6||Size: 100 ug||CAT.#: RP1010-100||Price: $484.00|
|Human Interleukin-6 (IL-6): Human Interleukin-6||Size: 1000 ug||CAT.#: RP1010-1000||Price: $3,175.00|
|Human IL-6 ELISA Kit: Human Interleukin-6 ELISA Kit||Size: 96 Wells||CAT.#: CL0410||Price: $517.00|
|Subculture Reagent Kit: 100 ml each of HBSS, Trypsin/EDTA & Trypsin Neutralizing Solution||Size: 1 Kit||CAT.#: 090K||Price: $55.00|
|Human IL-6, Animal Free: Human Interleukin-6, Animal-Free||Size: 20 ug||CAT.#: RP1010AF-20||Price: $213.00|
|Human IL-6, Animal Free: Human Interleukin-6, Animal-Free||Size: 100 ug||CAT.#: RP1010AF-100||Price: $533.00|
|Human IL-6, Animal Free: Human Interleukin-6, Animal-Free||Size: 1000 ug||CAT.#: RP1010AF-1000||Price: $3,492.00|
Baskar, K., S. Sur, V. Selvaraj and D. Agrawal. 2015. Functional constituents of a local serotonergic system, intrinsic to the human coronary artery smooth muscle cells. Molec Biol Repts, 42:1295-1307.
Boosani, C., K. Dhar, and D. Agrawal. 2015. Down-regulation of hsa-miR-1264 contributes to DNMT1-mediated silencing of SOCS3. Molec Biol Repts, DOI 10.1007/s11033-015-3882-x.
Gupta, M., S. Lee, S. Crowder, X. Wang, L. Hofmeister, C. Nelson, L. Bellan, C. Duvall, and H. Sung. 2015. Oligoproline-Derived Nanocarrier for Dual Stimuli-Responsive Gene Delivery. Journal of Materials Chemistry B, DOI: 10.1039/C5TB00988J.
Han, Y., Y. Cho, R. Ayon, R. Guo, K. Youssef, M. Pan, A. Dai, J. Yuan and A. Makino. 2015. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol, 309:L1027-L1036.
Harith, H., B. Di Bartolo, S. Cartland, S. Genner and M. Kavurma. 2015. Insulin promotes vascular smooth muscle cell proliferation and apoptosis via differential regulation of tumor necrosis factor-related apoptosis-inducing ligand. J Diabetes, 8:568-578.
Simone, T., S. Higgins, J. Archambeault, C. Higgins, R. Ginnan, H. Singer, and P. Higgins. 2015. A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage. Cellular Signalling, 27:923-933.
Yu, Y., s. Wise, P. Michael, D. Bax, G. Yuen, M. Hiob, G. Yeo, E. Filipe, L. Dunn, K. Chan, H. Hajian, D. Celermajer, A. Weiss and M. Ng. 2015. Characterization of Endothelial Progenitor Cell Interactions with Human Tropoelastin. PLoS ONE 10(6): e0131101.
Kiyan, Y., S. Tkachuk, D. Hilfiker-Kleiner, H. Haller, B. Fuhrman, and I. Dumler. 2014. oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. J. Mol. & Cell. Cardiol. 66:72-82.
Lange, M., T. Fujikawa, A. Koulova, S. Kang, M. Griffin, A. Lassaletta, A. Erat., E. Tobiash, C. Bianchi, N. Elmadhun, F. Selke, and A. Usheva. 2014. Arterial territory-specific phosphorylated retinoblastoma protein species and CDK2 promote differences in the vascular smooth muscle cell response to mitogens. Cell Cylcle, 13:315-323.
Lord, M., C. Chuang, J. Melrose, M. Davies, R. Iozzo and J. Whitelock. 2014. The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling. Matrix Biol, 35:112-122.
Dhar, K., K. Rakesh, D. Pankajakshan, and D.K. Agrawal. 2013. SOCS3 promotor hypermethylation and STAT3-NF-κB interaction downregulate SOCS3 expression in human coronary artery smooth muscle cells. Am. J. Physiology. 304:H776-H785.
Fujita, H., K. Miyadera, M. Kato, Y. Fujioka, H. Ochiiwa, J. Huang, K. Ito, Y. Aoyagi, T. Takenaka, T. Suzuki, S. Ito, A. Hashimoto, T. Suefuji, K. Egami, H. Kazuno, Y. Suda, K. Nishio, and K. Yonekura. 2013. The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile. Molecular Cancer Therapeutics. 12:2685-2696.
Lange, M. 2013. Artery Specific Differences in Cell Cycle Regulation are Associated with Serum Induced Proliferation of Vascular Smooth Muscle Cells. University of Applied Science Bonn-Rhine-Sieg, MSc dissertation.
Mociornita, A. 2013. The Role of Human Leukocyte Antigen-G in Cardiac Allograft Vasculopathy. University of Toronto, MSc dissertation.
Wu-Wong, J.R., M. Nakane, Y.-W. Chen, and W. Qiang. 2013. Different Effects of Calcidiol and Calcitriol on Regulating Vitamin D Receptor Target Gene Expression in Human Vascular Smooth Muscle Cells. J. CARDIOVASCULAR DISEASE. 1:15-20.
Albasanz-Puig, A., J. Murray, M. Namekata, and E.S. Wijelath. 2012. Opposing roles of STAT-1 and STAT-3 in regulating vascular endothelial growth factor expression in vascular smooth muscle cells. Biochem. & Biophys. Res. Comm. 428:179-184.
Crowder, S.W., M.K. Gupta, L.H. Hofmeister, A.L. Zachman, and H.-J. Sung. 2012. Modular polymer design to regulate phenotype and oxidative response of human coronary artery cells for potential stent coating applications. Acta Biomaterialia. 8:559-569.
Feng, G.-M., J.-H. Chen, C.-I. Lin, and J.-M. Yang. 2012. Effect of docosahexaenoic acid on hypoxia/reoxygenation injury in human coronary arterial smooth muscle cells. Eur J Nutr. 51:987-995.
Jemy, J. 2012. Does Human Leukocyte Antigen-G (HLA-G) Play a Role in Immunte Modulation and Vasculopathy in Heart Transplantation? Masters Thesis, U Toronto.
Khachigian, L. 2012. Vascular therapeutics. Patent US 8242090 B2.
Nivison‐Smith, L., and A.S. Weiss. 2012. Alignment of human vascular smooth muscle cells on parallel electrospun synthetic elastin fibers. Journal of Biomedical Materials Research Part A. 100:155-161.
Nivison-Smith, L., J. Rnjak, and A.S. Weiss. 2010. Synthetic human elastin microfibers: Stable cross-linked tropoelastin and cell interactive constructs for tissue engineering applications. Acta Biomaterialia. 6:354-359.
Zhou, J., G. Hu, and X. Wang. 2010. Repression of Smooth Muscle Differentiation by a Novel High Mobility Group Box-containing Protein, HMG2L1. Journal of Biological Chemistry. 285:23177-23185.
Zhang, M.-X., C. Zhang, Y.H. Shen, J. Wang, X.N. Li, Y. Zhang, J. Coselli, and X.L. Wang. 2008. Biogenesis of Short Intronic Repeat 27-Nucleotide Small RNA from Endothelial Nitric-oxide Synthase Gene. Journal of Biological Chemistry. 283:14685-14693.
Zhou, J., E. Blue, G. Hu, and P. Herring. 2008. Thymine DNA Glycosylase Represses Myocardin-induced Smooth Muscle Cell Differentiation by Competing with Serum Response Factor for Myocardin Binding. J Biol Chem, 283:35383-35392.
Wu, K., C. Huang, J. Wei, L. Tsai, C. Hsu, Y. Chen, J. Yang, and C. Lin. 2007. Vasodilator action of docosahexaenoic acid (DHA) in human coronary arteries in vitro. The Chinese journal of physiology. 50:164-170.
Jin, Y., E. Blue, and P. Gallagher. 2006. Control of Death-associated Protein Kinase (DAPK) Activity by Phosphorylation and Proteasomal Degradation. J Biol Chem, 281:39033-39040.
Owing, J. 2005. Smoking and health: new research. Nova Publishers. HCASMC
Wu, S.-N., P.-H. Lin, K.-S. Hsieh, Y.-C. Liu, and H.-T. Chiang. 2003. Behavior of Nonselective Cation Channels and Large-Conductance Ca2+-Activated K+ Channels Induced by Dynamic Changes in Membrane Stretch in Cultured Smooth Muscle Cells of Human Coronary Artery. Journal of Cardiovascular Electrophysiology. 14:44-51.
Wu, S.-N., H.-T. Chiang, F.-R. Chang, C.-C. Liaw, and Y.-C. Wu. 2003. Stimulatory Effects of Squamocin, an Annonaceous Acetogenin, on Ca2+-Activated K+ Current in Cultured Smooth Muscle Cells of Human Coronary Artery. Chemical Research in Toxicology. 16:15-22.
Khachigian, L.M., R.G. Fahmy, G. Zhang, Y.V. Bobryshev, and A. Kaniaros. 2002. c-Jun Regulates Vascular Smooth Muscle Cell Growth and Neointima Formation after Arterial Injury. Journal of Biological Chemistry. 277:22985-22991.
Khachigian, L.M., R.G. Fahmy, G. Zhang, Y.V. Bobryshev, and A. Kaniaros. 2002. c-Jun Regulates Vascular Smooth Muscle Cell Growth and Neointima Formation after Arterial Injury: INHIBITION BY A NOVEL DNA ENZYME TARGETING c-Jun. Journal of Biological Chemistry. 277:22985-22991.